Stay on Top of Changes to COVID-19 Management

Questions are popping up about changes with COVID-19 management...monoclonal antibodies (MAbs), remdesivir, etc.

It's partly because FDA has halted use of the MAbs bamlanivimab/etesevimab and casirivimab/imdevimab (Regen-COV)...since they don't work against the current Omicron variant.

Anticipate that the oral antiviral nirmatrelvir/ritonavir (Paxlovid) will be preferred for outpatients instead.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote